MedTrace Logo

Pain Research: Innovative Strategies With Marijuana

NCT03522324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 268

Last updated 2025-08-27

Study results available
· View outcomes & findings →

Summary

This study tests the effects of cannabinoid levels in blood on pain relief, inflammation, and cognitive dysfunction in chronic pain patients who choose to use edible cannabis. Over a two-week period, participants use an edible product of their choice. Blood levels of 9-delta-tetrahydrocannabinol (THC) and cannabidiol (CBD) will be measured before, during, and after the two-week exposure period to determine whether there are associations with pain, inflammation, sleep, physical activity, anxiety/depression, and cognitive dysfunction. After the two-week self-administration period, participants will be followed for six months to collect self-report data on cannabis use, pain levels, sleep quality, and mental health symptoms.

Conditions

Interventions

DRUG

Cannabis Edible

Self-Directed Use (ad-libitum)

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Colorado State University

    collaborator OTHER

  • University of Colorado, Boulder

    lead OTHER

Principal Investigators

  • Cinnamon Bidwell, PhD · Institute of Cognitive Science, University of Colorado, Boulder

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2023-04-10
Completion
2023-10-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03522324 on ClinicalTrials.gov